Curis, Inc. Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2014. Although the request metadata refers to 2014 Q4, this filing is an annual report and includes full-year results and unaudited quarterly data. Curis is a cancer-focused biotechnology company; its portfolio was primarily early-stage, with Erivedge marketed by Genentech and Roche.
Financial performance and liquidity
| Metric | FY 2014 | FY 2013 |
|---|---|---|
| Revenue | $9.84 million | $15.00 million |
| Operating loss | $15.86 million | $9.42 million |
| Net loss | $18.73 million | $12.32 million |
| Net loss per share | $0.22 | $0.15 |
| Research and development expense | $13.66 million | $12.93 million |
| General and administrative expense | $11.71 million | $11.29 million |
| Net cash used in operating activities | $16.81 million | $9.54 million |
| Cash, cash equivalents and investments | $50.54 million | $68.91 million |
| Working capital | $42.15 million | $53.61 million |
- Revenue comprised $6.76 million of Erivedge royalties, $3.00 million of Genentech milestone/license revenue, and $0.09 million of net research and development revenue. Genentech accounted for approximately 100% of 2014 revenue.
- Erivedge royalties increased 71% year over year, but total revenue declined 34%, mainly because 2013 included $10 million in approval-related license fees and $0.65 million from the Leukemia & Lymphoma Society (LLS), neither of which recurred at the same level in 2014.
- Cash and investments declined about $18.37 million. Operating cash use rose from 2013; 2014 financing activities used $1.30 million, while investing activities provided $16.27 million, mainly from net investment maturities and purchases.
- Curis Royalty’s BioPharma-II loan carried 12.25% annual interest. At year-end, principal and accrued interest were $28.70 million gross; balance-sheet debt was $28.30 million net of issuance costs. Erivedge royalty proceeds are assigned to repayment, and management estimated repayment in 2017. The loan is intended to be non-recourse to Curis, but is secured by the royalty subsidiary’s assets and royalty stream.
- Curis reported an accumulated deficit of $779.56 million and stated it had never been profitable. Management expected available capital at year-end to support current and planned operations into 2016.
Material changes and operating developments
- CUDC-907: The Phase 1 dose-escalation stage was completed and recommended dosing established in Q4. In a preliminary group of eight heavily pretreated DLBCL patients, three had confirmed partial responses and one had a complete response. A separate Phase 1 solid-tumor study began in Q4. The company expected to present data in 2015 and planned a randomized, registration-directed Phase 2 study in relapsed/refractory DLBCL in the second half of 2015.
- CUDC-427: The FDA lifted a partial clinical hold in March 2014 following a patient death involving liver failure after treatment discontinuation. Curis completed dose escalation and selected 300 mg daily on a 14-days-on, 7-days-off schedule; an expansion cohort was planned for 2015.
- Aurigene collaboration: Entered in January 2015, after the fiscal year-end, the collaboration covers immuno-oncology and precision-oncology programs, including PD-L1 and IRAK4. Curis planned to exercise options and file IND applications in 2015. It issued Aurigene 17.12 million shares, approximately 19.9% of pre-transaction shares, and assumed potential option, milestone, and royalty payments. The first two programs each carry specified $3 million option-exercise, $3 million IND-acceptance, and $4 million fifth-patient dosing payments.
- CUDC-305: Debiopharm decided not to advance Debio 0932 to Phase 2 after inconclusive Phase 1 results. Rights returned to Curis under a February 2015 transition agreement. Curis paid $750,000 and assumed contingent milestones, royalties, and sublicense-sharing obligations; it was evaluating studies in other indications.
- Erivedge: It remained approved for advanced basal cell carcinoma in the U.S., Australia and other countries, with conditional EU approval. The STEVIE safety study had enrolled approximately 1,200 patients. A Roche Phase 2 idiopathic pulmonary fibrosis study was suspended before enrolling patients pending protocol changes. A competing Hedgehog inhibitor under regulatory review could reduce Curis’s royalty rate in affected territories.
Outlook, risks and unusual items
- No financial earnings or revenue guidance was provided. Management’s stated outlook was continued operating losses and cash use, with capital expected to fund planned operations into 2016; further funding would depend on collaboration payments, expense control, and new financing or partnerships.
- Revenue and near-term cash generation are highly concentrated in Erivedge-related milestones and royalties. Most royalty proceeds were expected to service the BioPharma-II debt until repayment, limiting their availability to fund operations.
- Key risks include clinical-trial failure or delay, safety and regulatory setbacks, dependence on Genentech/Roche and Aurigene, competition, uncertain reimbursement, intellectual-property challenges, reliance on external manufacturing, and the possibility that additional capital may be unavailable or dilutive.
- The Aurigene share issuance occurred after year-end and materially expands the share count; 103,178,454 common shares were outstanding as of February 18, 2015. The filing also reports that legacy warrants expired unexercised in January 2015, eliminating the related warrant liability.
- Q4 2014 unaudited results were revenue of $1.99 million, operating loss of $4.81 million, net loss of $5.69 million, and loss per share of $0.07.
- PwC issued an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective as of December 31, 2014. Curis reported no material legal proceedings.
Important facts for investors to verify
- Subsequent Erivedge sales, royalty rates, and the timing and terms of BioPharma-II debt repayment, including the impact of competing products.
- Whether CUDC-907’s early response observations are sustained in larger studies and whether the planned Phase 2 trial proceeds on schedule.
- Progress, option exercises, IND submissions, and cash obligations under the Aurigene collaboration, alongside the dilution from the 17.12 million-share issuance.
- Curis’s updated cash runway, operating cash burn, and any financing or partnering plans beyond the stated runway into 2016.
- Whether CUDC-305 is restarted clinically and what additional development, manufacturing, milestone, and royalty costs follow the Debiopharm transition.